Last reviewed · How we verify

NCT06617078: HIGHOXFILD

Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild

Not yet recruiting NA Last updated 27 September 2024
What this trial tests

NA trial testing long-term oxygen therapy (LTOT) in ILD in 42 participants. Not yet recruiting.

Timeline
15 October 2024
Primary endpoint
15 October 2026
15 October 2026

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment42
Start date15 October 2024
Primary completion15 October 2026
Estimated completion15 October 2026

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with ILD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic respiratory failure and persistent breathlessness in whom LTOT has already been initiated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ILD

Currently open trials in the same condition.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing